Ronald Fleming
Executive Director, Clinical Development Daiichi Sankyo
Ronald Fleming is Executive Director of Clinical Development at Daiichi Sankyo. With a career spanning senior roles in oncology clinical development at GSK and Bristol Myers Squibb, he brings deep expertise in advancing first in human and early phase therapeutics as well as late-stage clinical development. At Daiichi Sankyo, Ronald plays a key role in steering the clinical strategy behind the industry leading DXd ADC portfolio, helping translate the platform’s potent, tumor targeted design into meaningful patient impact across multiple cancers.
Seminars
Tuesday 13th October 2026
Presentation Preview: Contextualizing Clinical Success of Enhertu Combination to Secure First- Line Approval in HER2+ Metastatic Breast Cancer
- Envisioning potential for Enhertu to move from advanced to early oncology settings
- Delving into the clinical data and first-line approval of Enhertu combination therapy in HER2+ metastatic breast cancer
- Laying out rationale-driven research to identify combination partners complimentary to Enhertu mechanism
